Cassava Sciences (SAVA) Competitors

Tyra Biosciences (NASDAQ:TYRA) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Which has better earnings and valuation, TYRA or SAVA?

Tyra Biosciences is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$69.13M	-$1.51	-6.04
Cassava Sciences	N/A	N/A	-$97.22M	-$1.45	-1.09

Does the media favor TYRA or SAVA?

In the previous week, Tyra Biosciences and Tyra Biosciences both had 16 articles in the media. Tyra Biosciences' average media sentiment score of 0.68 beat Cassava Sciences' score of -0.16 indicating that Tyra Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Cassava Sciences	0 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Is TYRA or SAVA more profitable?

Tyra Biosciences' return on equity of -24.56% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-24.56%	-23.31%
Cassava Sciences	N/A	-88.05%	-64.98%

Does the MarketBeat Community favor TYRA or SAVA?

Cassava Sciences received 62 more outperform votes than Tyra Biosciences when rated by MarketBeat users. However, 76.60% of users gave Tyra Biosciences an outperform vote while only 64.47% of users gave Cassava Sciences an outperform vote.

Company	Underperform	Outperform
Tyra Biosciences	Outperform Votes 36 76.60%	Underperform Votes 11 23.40%
Cassava Sciences	Outperform Votes 98 64.47%	Underperform Votes 54 35.53%

Which has more risk & volatility, TYRA or SAVA?

Tyra Biosciences has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -1.24, suggesting that its share price is 224% less volatile than the S&P 500.

Do analysts prefer TYRA or SAVA?

Tyra Biosciences presently has a consensus target price of $30.83, suggesting a potential upside of 237.90%. Cassava Sciences has a consensus target price of $54.50, suggesting a potential upside of 3,360.32%. Given Cassava Sciences' higher possible upside, analysts clearly believe Cassava Sciences is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cassava Sciences	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Do insiders & institutionals believe in TYRA or SAVA?

84.1% of Tyra Biosciences shares are held by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are held by institutional investors. 15.4% of Tyra Biosciences shares are held by insiders. Comparatively, 9.0% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Tyra Biosciences beats Cassava Sciences on 10 of the 14 factors compared between the two stocks.